Cellworks Singula™ Predicts Personalized Therapy Responses for AML and MDS Patients with Higher Accuracy than Physician Prescribed Treatments
myCare Studies Show Cellworks Multi-omics Biosimulation is a Superior Predictor of Complete…
Cellworks Singula™ Predicts Personalized Therapy Responses for Pancreatic Cancer Patients with 94% Accuracy
myCare Study Shows Cellworks Multi-omics Biosimulation is a Superior Predictor of Therapy…
Blood Advances Publishes Cellworks Prospective Genomic Biosimulation Study that Predicts Cancer Therapy Response with 90% Accuracy
Study Uses NGS Data with Biosimulation to Predict Drug Response in AML and MDS Patients
…
Cellworks myCare™ Clinical Trial Transforms NGS Data into Personalized Cancer Therapy Actions
New Trial Biosimulates Efficacy of Cancer Therapies Using Molecular Genetic Aberration Data…